Marketing Fraud
RegulationWatch reporting on marketing fraud matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- Marketing Fraud
Veloxis pays over $46 million and enters deferred prosecution over kickbacks
Veloxis Pharmaceuticals Inc. has agreed to pay more than $46 million to resolve criminal and civil allegations that it paid kickbacks to boost prescriptions of its kidney transplant drug Envarsus XR. The resolution includes a deferred prosecution agreement, a $34.45 million False Claims Act settlement and a $1.55 million Sunshine Act penalty — the largest since the law's passage.
- Marketing Fraud
Takeda pays $13.6 million over Trintellix speaker program kickback allegations
Takeda Pharmaceuticals U.S.A. Inc. has agreed to pay $13,670,921 to resolve Department of Justice allegations that it paid kickbacks to healthcare providers, in the form of speaker honoraria and high-end meals, to induce prescriptions of the antidepressant Trintellix. The government alleged the conduct caused false claims to Medicare and other federal programmes.
